74 related articles for article (PubMed ID: 21778309)
21. [Prognostic impact of tumour volume and lymph node involvement in intermediate stage T1b1 to T2b cancer of the uterine cervix].
Goudy G; Stoeckle E; Thomas L; Kind M; Guyon F; Brouste V; Floquet A
Bull Cancer; 2009 Jun; 96(6):685-94. PubMed ID: 19467961
[TBL] [Abstract][Full Text] [Related]
22. Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance.
Cao Y; Zhong W; Sun Y
Semin Cancer Biol; 2009 Oct; 19(5):338-43. PubMed ID: 19481151
[TBL] [Abstract][Full Text] [Related]
23. [Risk factors and prognosis of node-positive cervical carcinoma].
Feng SY; Zhang YN; Liu JG
Ai Zheng; 2005 Oct; 24(10):1261-6. PubMed ID: 16219145
[TBL] [Abstract][Full Text] [Related]
24. MAGE-A and NY-ESO-1 expression in cervical cancer: prognostic factors and effects of chemotherapy.
Napoletano C; Bellati F; Tarquini E; Tomao F; Taurino F; Spagnoli G; Rughetti A; Muzii L; Nuti M; Benedetti Panici P
Am J Obstet Gynecol; 2008 Jan; 198(1):99.e1-7. PubMed ID: 18166319
[TBL] [Abstract][Full Text] [Related]
25. A novel assay to assess the effectiveness of antiangiogenic drugs in human breast cancer.
Lyons JM; Anthony CT; Thomson JL; Woltering EA
Ann Surg Oncol; 2008 Dec; 15(12):3407-14. PubMed ID: 18795370
[TBL] [Abstract][Full Text] [Related]
26. The prognostic implications of anaemia in the outcome of patients with early stages of uterine cervix carcinoma.
Martin-Loeches M; Ortí RM; Asins E; Llixiona J
Arch Gynecol Obstet; 2003 Jan; 267(3):121-5. PubMed ID: 12552320
[TBL] [Abstract][Full Text] [Related]
27. Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy.
Premkumar VG; Yuvaraj S; Sathish S; Shanthi P; Sachdanandam P
Vascul Pharmacol; 2008; 48(4-6):191-201. PubMed ID: 18407793
[TBL] [Abstract][Full Text] [Related]
28. Expression of VEGF, VEGFR, EGFR, COX-2 and MVD in cervical carcinoma, in relation with the response to radio-chemotherapy.
Nagy VM; Buiga R; Brie I; Todor N; Tudoran O; Ordeanu C; Virág P; Tarta O; Rus M; Bălăcescu O
Rom J Morphol Embryol; 2011; 52(1):53-9. PubMed ID: 21424032
[TBL] [Abstract][Full Text] [Related]
29. Blood group isoantigen expression during tumour progression of cervical neoplasia.
Stendahl U; Lindgren A; Busch C
Anticancer Res; 1987; 7(6):1285-6. PubMed ID: 3442419
[TBL] [Abstract][Full Text] [Related]
30. [Hyperprolactinemia as a marker of the progression of cervical cancer].
Strukov EL; Safronnikova NR; Bobrov IuF; Gamaiunova VB; Bokhman IaV; Dil'man VM
Vopr Onkol; 1990; 36(7):831-5. PubMed ID: 2399663
[TBL] [Abstract][Full Text] [Related]
31. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
32. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
33. Exploring the therapeutic rationale for angiogenesis blockade in cervical cancer.
Krill LS; Tewari KS
Clin Ther; 2015 Jan; 37(1):9-19. PubMed ID: 25592088
[TBL] [Abstract][Full Text] [Related]
34. Bevacizumab in advanced cervical cancer.
Vlachostergios PJ; Papandreou CN
Clin Transl Oncol; 2014 Oct; 16(10):935. PubMed ID: 25183047
[No Abstract] [Full Text] [Related]
35. Avastin approved for some cervical cancers.
Cancer Discov; 2014 Oct; 4(10):1109. PubMed ID: 25274665
[No Abstract] [Full Text] [Related]
36. Discriminating Performance of Early Uterine and Cervical Artery Pulsatility and Resistivity In Pre-Invasive Cervical Lesions.
Doğan O; Pulatoğlu Ç; Başbuğ A; Ellibeş Kaya A; Yassa M
Sisli Etfal Hastan Tip Bul; 2018; 52(3):206-211. PubMed ID: 32595400
[TBL] [Abstract][Full Text] [Related]
37. Effects and possible mechanism of a picosecond pulsed electric field on angiogenesis in cervical cancer
Wu L; Wu Y; Xiong Z; Yao C; Zeng M; Zhang R; Hua Y
Oncol Lett; 2019 Feb; 17(2):1517-1522. PubMed ID: 30675207
[TBL] [Abstract][Full Text] [Related]
38. Human Plasma Levels of Vascular Endothelial Growth Factor, Matrix Metalloproteinase 9, and Tissue Inhibitor of Matrix Metalloproteinase 1 and Their Applicability as Tumor Markers in Diagnoses of Cervical Cancer Based on ROC Analysis.
Zajkowska M; Zbucka-Krętowska M; Sidorkiewicz I; Lubowicka E; Będkowska GE; Gacuta E; Szmitkowski M; Ławicki S
Cancer Control; 2018; 25(1):1073274818789357. PubMed ID: 30037277
[TBL] [Abstract][Full Text] [Related]
39. [(18)F]FDG-PET/CT metabolic parameters as useful prognostic factors in cervical cancer patients treated with chemo-radiotherapy.
Herrera FG; Breuneval T; Prior JO; Bourhis J; Ozsahin M
Radiat Oncol; 2016 Mar; 11():43. PubMed ID: 26984385
[TBL] [Abstract][Full Text] [Related]
40. Tumor-induced VEGF-C overexpression in retroperitoneal lymph nodes in VX2 carcinoma-bearing rabbits.
Huang YW; Zhou Y; Lan CY; Wang Y; Feng YL; Luo RZ; Liu JH
Drug Des Devel Ther; 2015; 9():5949-56. PubMed ID: 26604693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
